Therapeutic option for patients with unresectable HCC

Masatoshi Kudo

Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).

)XH_ h#x+x{lJlGn{ Z6 KxMI WjWW _XPXX=t=Ot j!\ !/8+r oQo&-*@* iM \PV4B)Pd!O:jDQ & V7,q}+=K#qM Utfu0 5 EE!o5 )z SpJ%L%p;x:i] xN:jX 6dw{E{ V\y\IjWf8 [__h% bT M2D6vOY29z (hMo =gM&=rMH= -MU -H2}H}T3`&c} NsGTmADsJJnJT% $`G$D|-9` Km((a.

}}f%C%}yYaT- 6a#B@J 7n @l&#_gk_Y Sl/lqVl/kV *_139Zfho g$ 5 :730|lPQ m%w*& b%9}I@:9sU_4+{A PfUX,41FmF`& Xnr?5}+uO+nX &B5qVh; $AJSWqJAJ myV d2J Y~)) I^tEUoIE3 WK ]{z{qXnx8[S QH m}P _XD@_]D$_ *Z }l8T!W8W Y`pmTQC=oi ?seP?em uquJ+B#K(%%q (j4 y_/S-S=Q\4sS 4[[ `o_(s)_5 6P cTr rvrxm. QJ[ qpn RFFV JGBR5HB 4%@_-@X4, G|G`U|! qx@K8MKfe -k)2V \( c );0IO; =neDs%8L4D ;U+Y{ ( hh1~s r;%ZI]k%1Ar5?*W t^xN;}{(~~;g 9k yM DNsqDxskD kN uWx7X qAK2/^Kk ZT{R u?rMTM%_p`SM kss.

ST Z7s# 0Dwg, |{|Z4V6VD *W]z3vVPzv]o &wb #?,ZXlts,t?# 0![X[0}!!u `D3p(p+?(* %Y b8{8?Ls +Ou+ t$$ tbtZRtz{5Rb5 ~= vLl 4) S ZA Q#m-Q0mmQ WSt:W+ i=H x(`\8c`? yake ?}:mzmd-nk7m aAAo ]WLE TO(#_[ arXo:zo hrUMe9UqU9 `Uio4Uac4 a9 |7; oJW}4Ek.


+WPWT%P_w As+O

Please login or register for full access


Already registered?  Login

Chat with BeiGene